Belfast-based Contract Research Organisation (CRO) Fusion Antibodies (AIM: FAB) announced on Tuesday that it has entered into a collaboration agreement with the National Cancer Institute (NCI), utilising its OptiMAL technology for discovering novel antibodies against cancer targets.
The partnership spans up to two years, with Fusion granting NCI access to OptiMAL for validating the technology in NCI's laboratories. Successful results will be jointly published and NCI will retain identified antibodies.
NCI, a key cancer research and training agency under the US National Institutes of Health, aims to leverage Fusion's expertise in pre-clinical antibody discovery for potential therapeutic applications.
Fusion Antibodies specialises in antibody engineering for therapeutic drug and diagnostic uses. The company provides a range of services, including antibody design, production, purification, sequencing and humanisation. With a mission to facilitate timely and cost-effective product development, Fusion Antibodies has a global client base, including top pharmaceutical companies.
The company's growth strategy involves leveraging technological advances and scientific innovations to expedite drug development processes. The collaboration aligns with Fusion's commitment to advancing healthcare solutions in a dynamic market, with the global monoclonal antibody therapeutics market projected to exceed USD445bn by 2028.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration